Besides, it should be emphasized that IL-6 is a critical cytokine, which induces the transcription of MT I/II both in the liver [37–39] and in the brain [35, 40], leading eventually to the marked cytoprotective and neuroprotective outcome, as it has been shown in various physiological conditions [16, 41] and in EAE [42], MS, [43] and other types of brain injury [13, 44, 45]. The gene discussed is IL6; the disease is myeloid sarcoma.